Post

New research · Ophthalmology
Ocular immunology and inflammation · 14h
Cohort studyOcular immunology and inflammation · 2026

Efficacy of Adalimumab Therapy for Non-Infectious Uveitis in Japanese Patients: Methotrexate Concomitance Across Different Uveitis Etiologies and the Effect of Dose Spacing.

Tatsuya Sakamoto, Tomona Hiyama, Mao Tanabe … Yosuke Harada
Read paper
OphthalmologyCohort study

Most patients on adalimumab had inactive uveitis after 12 months of treatment

Efficacy of Adalimumab Therapy for Non-Infectious Uveitis in Japanese Patients: Methotrexate Concomitance Across Different Uveitis Etiologies and the Effect of Dose Spacing.

Tatsuya Sakamoto … Yosuke Harada
Ocular immunology and inflammation · 2026
Purpose

To evaluate the long-term efficacy of adalimumab (adalimumab) in Japanese patients with non-infectious uveitis (non-infectious uveitis), with particular attention to etiologic differences in methotrexate (methotrexate) requirements and the feasibility of adalimumab dose spacing.

Methods

This retrospective study included patients with chronic non-infectious uveitis or sclerouveitis treated with adalimumab for more than 6 months.

n = 160 eyes
Results
61.5%
checked eye by eye, most had no active inflammation after a year
n = 160 eyes
More results

Adalimumab reduced systemic corticosteroid dosage (mean 13.7 mg/day at baseline to 0.9 mg/day at 12 months; Wilcoxon signed-rank test p < 0.0001 for baseline-to-12-month change) and improved best-corrected visual acuity (mixed-effects model: p = 0.035 at 12 months) and inflammation markers.

More results

Patients with late- or chronic-stage Vogt-Koyanagi-Harada disease/sympathetic ophthalmia showed a trend toward a higher requirement for methotrexate concomitance than Behçet's disease patient.

Over half of the 24 patients attempting dose spacing relapsed (14/24), but disease control was regained by shortening intervals.

“
Conclusion · 1 of 2

Adalimumab effectively controlled non-infectious uveitis and provided significant steroid-sparing benefits.

Conclusion · 2 of 2

Possible etiology-dependent differences in methotrexate requirements and relapse risk during dose spacing, support the optimization of individualized, closely monitored treatment.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment